

Appendix 4D

Half-Year Consolidated Financial Report

Introduced 1/1/2003.

Name of Entity	OBJ LIMITED
ABN	72 056 482 636
Financial Period Ended	31 DECEMBER 2016
Previous Corresponding Reporting Period	31 DECEMBER 2015

Results for Announcement to the Market

	\$'000	Percentage increase /(decrease) over previous corresponding period
Revenue	1,440	Up 3%
Loss for the period	(2,453)	Up 107%
Loss attributable to members of the parent entity	(2,453)	Up 107%
Dividends (distributions)	Amount per security	Franked amount per security
Final Dividend	Nil	Nil
Interim Dividend	Nil	Nil
Previous corresponding period *	Nil	Nil
Record date for determining entitlements to the dividends (if any)	N/A	
Brief explanation of any of the figures reported above necessary to enable the figures to be understood:		
Refer to the Review of Operations section of the Directors' Report included in Attachment 1.		

The half-year consolidated financial report is to be read in conjunction with the most recent annual financial report.

Dividends

Date the dividend is payable	N/A
Record date to determine entitlement to the dividend	N/A
Amount per security	N/A
Total dividend	N/A
Amount per security of foreign sourced dividend or distribution	N/A
Details of any dividend reinvestment plans in operation	N/A
The last date for receipt of an election notice for participation in any dividend reinvestment plans	N/A

NTA Backing

	Current Period	Previous corresponding period
Net tangible asset backing per ordinary security	\$0.004	\$0.005

Other Significant Information Needed by an Investor to Make an Informed Assessment of the Entity's Financial Performance and Financial Position

Refer to the Review of Operations section of the Directors' Report included in Attachment 1.

Commentary on the Results for the Period

The earnings per security and the nature of any dilution aspects :

Refer to the Statement of Comprehensive Income in Attachment 1.

Returns to shareholders including distributions and buy backs :

N/A

Significant features of operating performance :

Refer to the Review of Operations section of the Directors' Report included in Attachment 1.

The results of segments that are significant to an understanding of the business as a whole:

Refer to the Review of Operations section of the Directors' Report included in Attachment 1.

Discussion of trends in performance :

Refer to the Review of Operations section of the Directors' Report included in Attachment 1.

Any other factor which has affected the results in the period or which are likely to affect results in the future, including those where the effect could not be quantified:

N/A

Control Gained Over Entities Having Material Effect

Name of entity (or group of entities)	N/A
Date control gained	N/A
Consolidated profit / (loss) from ordinary activities since the date in the current period on which control was acquired	N/A
Profit / (loss) from ordinary activities of the controlled entity (or group of entities) for the whole of the previous corresponding period	N/A

Loss of Control Gained Over Entities Having Material Effect

Name of entity (or group of entities)	N/A
Date control lost	N/A
Consolidated profit / (loss) from ordinary activities for the current period to the date of loss of control ('\$000)	N/A
Profit / (loss) from ordinary activities of the controlled entity (or group of entities) while controlled for the whole of the previous corresponding period ('\$000)	N/A

Details of Associates and Joint Venture Entities


Name of Entity	Percentage Held		Share of Net Profit	
	Current Period	Previous Period	Current Period	Previous Period
N/A				
Aggregate Share of Net Profits				

Audit/Review Status

This half-year consolidated financial report is based on accounts to which one of the following applies: (Tick one)			
The accounts have been audited		The accounts have been subject to review	X
The accounts are in the process of being audited or subject to review		The accounts have not yet been audited or reviewed	
If the accounts have not yet been audited or subject to review and are likely to be subject to dispute or qualification, a description of the likely dispute or qualification: <p style="text-align: center;">N/A</p>			
If the accounts have been audited or subject to review and are subject to dispute or qualification, a description of the dispute or qualification: <p style="text-align: center;">N/A</p>			

Attachments Forming Part of Appendix 4D

Attachment #	Details
1	Interim Consolidated Financial Report

Signed By (Director)	
Print Name	Jeffrey Edwards
Date	27 th February 2017

OBJ LIMITED
A.B.N. 72 056 482 636

DIRECTOR'S REPORT

The directors present their consolidated financial statements on the results of OBJ Limited and its controlled entities for the financial half-year ended 31 December 2016.

Directors

The names of directors in office at any time during or since the end of the period are:

Mr Glyn Gregory Horne Denison
Mr Jeffrey David Edwards
Dr Christopher John Quirk

Directors have been in office since the start of the financial year to the date of this report.

Operating Result

The net consolidated loss of the Consolidated Entity after providing for income tax amounted to \$2,452,847 (31 December 2015: loss of \$1,185,313).

Review of Operations

Overview

The Company has continued with its strong cash management, with cash at the end of December 2016 remaining at \$5.56 million and is expecting the R&D tax rebate over the March quarter of further \$1.23 million. The Company continues to operate in a strong cash position.

The Company also has commenced receiving licensing income from Procter & Gamble (P&G) for their Wave I product incorporating OBJ's microarray technology. The product is to be distributed across several Asian countries including China, Japan and South Korea with two P&G brands.

The half-year to 31 December 2016 was a very successful year highlighted by the support from P&G for the planned inclusion of OBJ's microarray technology into various P&G products. The extension of the Product Development Agreement (PDA) until 2021 and the Master License Agreement (MLA) both executed in 2016 have together given OBJ an excellent framework to streamline the licensing of multiple products containing OBJ's microarray technology. The Licensing Term Sheet covering the Wave II product was executed during the period making it the second license under the MLA. The Company has been informed by P&G that Wave II will commence distribution during the 2017 calendar year.

The Company continues to invest in the development and potential commercialisation of its own products incorporating its various technologies in end-user applications. The potential for the personalisation, *BodyGuard*, DCE and surface hygiene product applications continues to grow as the Company exposes prototype developments for testing to commercial partners.

Procter & Gamble

The Company has received the first licensing revenues for the introduction of the Eye Wand by P&G's Olay brand in China. It is understood that the SK-II brand will similarly commence distribution during the third and fourth quarters of the financial year in other Asian countries.

The P&G relationship continues its very constructive pathway with P&G committing to a second OBJ technology to sit alongside the microarray already committed to P&G for the beauty and grooming market sector.

OBJ LIMITED
A.B.N. 72 056 482 636

DIRECTOR'S REPORT (continued)

Review of Operations (continued)

Procter & Gamble (continued)

This is a very exciting opportunity for growth by the Company and it is expected negotiations will be completed during the third quarter of the financial year.

This project remains highly confidential but is a potential "game changer" in the manner in which skin care is applied, optimised and centrally managed and will require careful consideration as to the steps of development and how consumer feedback is progressively introduced to the final specifications. The commercial negotiations by the parties leading to this position have taken place over an extended twelve-month duration.


Nevertheless, specialised teams from both companies have been assembled to drive the project forward immediately upon completion of the present commercial negotiations.

There are two additional products under development for P&G that utilise the OBJ microarray technology and these are all expected to move through licensing with Term Sheets to be added to the MLA with P&G. A further two products are presently under development and are expected to join the others when completed. This family of products across multiple brands will provide an excellent licensing platform for OBJ in future years. The commercialisation of the second technology will only add to the success enjoyed by the parties for the initial microarray licensing.

In addition, three new Work Plans are in negotiation with P&G for the use of microarray and other technology platforms for use across several new market sectors and brands of P&G.

The P&G relationship is fundamental to OBJ for its immediate future and justifiably is attracting a lot of focus from OBJ's management team at this time.

Programmable Array Device Platforms



Every consumer and every product is unique. ConnectBeauty™ customises the delivery of skin care actives for the consumer's unique skin type, ethnicity, age, and climate.

The Coty relationship remains in place and OBJ has agreed to undertake a testing program in its Leederville laboratory of new formulations that are intended to be used by Coty. Once these have been completed, Coty intends to run further consumer work to assess the effect of the new formulations with consumers. The whole development program has now been updated to reflect this revitalisation of the Coty work conducted over the past three years.

We await the outcomes of the forthcoming laboratory testing.

The Company continues to develop both the hardware and software for use of the programmable device with a variety of new applicators. Discussions also continue with several very interested parties relating to the next steps for possible commercialisation.

OBJ LIMITED
A.B.N. 72 056 482 636

DIRECTOR'S REPORT (continued)

Review of Operations (continued)

BodyGuard Program



The Company continues to work with several interested parties to commercialise the *BodyGuard* opportunities. One North American party is intending to move down the pathway that includes an NSAID combined with other active ingredients for a specific market sector.

This will entail clinical trials to be conducted with such a new formulation and the protocol for this is presently being negotiated with the

potential partner and an independent university.

A second series of discussions is taking place for the potential incorporation of the *BodyGuard* product range into their existing delivery products. A development and testing program is being prepared for this separate market sector.

Discussions are also continuing with other potential partners as the *BodyGuard* program gains further traction and one of these may also access another market sector from the first two.

Expanding Internal Programs

The Company is progressing with several additional value-added projects in Surface Penetration/Hygiene and e-Skin, the e-commerce version of the programmable Dermaportation wand technology.

The Company is currently working with selected partners in areas as diverse as pharmaceuticals, analgesics, multi-functional skin care products and musculoskeletal joint pain management.

During the period, the first potential interest from a partnering pharmaceutical company in OBJ's Dynamically Configurable Emulsions (DCE) technology is leading to an exciting testing program being developed. DCE is the ability to create liquid patches and has wide ranging potential applications.

value-added projects in Surface



The DCE platform is now highly sought after by both existing and prospective partners of OBJ as a breakthrough technology.



OBJ LIMITED
A.B.N. 72 056 482 636

DIRECTOR'S REPORT (continued)

Review of Operations (continued)

Administration

Over the period, OBJ has fitted out its new skin laboratory at its Leederville headquarters which greatly increases its capacity to undertake very complex skin penetration studies on behalf of potential partners. The addition of a third skin penetrometer machine and the new laboratory layout has greatly facilitated the increase in capacity.

The case involving the convertible note that expired in June 2012 continues in the Supreme Court and the Company has retained legal counsel as appropriate.

Intellectual Property

The Company's Intellectual Property Protection programs continued to expand during the period with the acceptance by the USA Patent Office and the Japanese Patent Office for oral health and skin delivery respectively.

The forthcoming granting of skin care and oral healthcare patents in these significant and strategic markets adds significantly to the value of the Company's IP portfolios.

Principal Activities


The principal activities of the Consolidated Entity during the financial half-year ended 31 December 2016 were research and development for its Dermaportation and ETP transdermal drug delivery technologies.

There were no significant changes in the nature of the Consolidated Entity's principal activities during the financial half-year other than those referred to in the Review of Operations.

Auditor's Independence Declaration

In accordance with the Audit Independence requirements of the Corporations Act 2001, the directors have received and are satisfied with the "Audit Independence Declaration" provided by OBJ Limited external auditors RSM Australia Partners. The Audit Independence Declaration is included within this consolidated financial report.

Signed in accordance with a resolution of the board of directors pursuant to section 306(3)(a) of the Corporations Act 2001.



Jeffrey Edwards
Director

Dated this 27th day of February 2017

RSM Australia Partners

8 St Georges Terrace Perth WA 6000

GPO Box R1253 Perth WA 6844

T +61 (0) 8 92619100

F +61 (0) 8 92619111

www.rsm.com.au

AUDITOR'S INDEPENDENCE DECLARATION


As lead auditor for the review of the financial report of OBJ Limited for the half-year ended 31 December 2016, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- (i) the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- (ii) any applicable code of professional conduct in relation to the review.



RSM

RSM AUSTRALIA PARTNERS



TUTU PHONG
Partner

Perth, WA
Dated: 27 February 2017

**CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE HALF-YEAR ENDED 31 DECEMBER 2016**

	31 Dec. 2016 \$	31 Dec. 2015 \$
Revenue	1,439,943	1,395,545
Net foreign exchange (loss)/gain	(164)	2,376
Bad debts written off	--	(60,961)
Borrowing costs	(7,004)	(7,002)
Depreciation expenses	(73,057)	(31,841)
Administration fees	(238,970)	(241,274)
Auditor's remuneration	(12,000)	(11,500)
Consultants and consultants benefits expenses	(788,713)	(574,500)
Directors and employees benefits expenses	(2,192,870)	(947,095)
Legal costs	(26,248)	(34,008)
Materials and requisites	(16,506)	(12,356)
Occupancy expenses	(70,099)	(61,408)
Patent fees	(39,200)	(58,042)
Product design and trial testing expenses	(116,076)	(202,594)
Travel and accommodation	(37,767)	(62,560)
Other expenses	(274,116)	(278,093)
Loss before income tax	(2,452,847)	(1,185,313)
Income tax expense	--	--
Loss for the period	(2,452,847)	(1,185,313)
Other comprehensive income	--	--
Total comprehensive loss for the period	(2,452,847)	(1,185,313)
Loss attributable to:		
Members of the parent entity	(2,452,847)	(1,185,313)
Basic and diluted losses per share (cents per share)	<u>(0.14)</u>	<u>(0.07)</u>

The above consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2016**

	Note	31 Dec. 2016 \$	30 Jun. 2016 \$
CURRENT ASSETS			
Cash and cash equivalents		5,560,028	7,334,205
Trade and other receivables		1,364,822	165,507
TOTAL CURRENT ASSETS		<u>6,924,850</u>	<u>7,499,712</u>
NON CURRENT ASSETS			
Plant and equipment		423,611	343,391
TOTAL NON CURRENT ASSETS		<u>423,611</u>	<u>343,391</u>
TOTAL ASSETS		<u>7,348,461</u>	<u>7,843,103</u>
CURRENT LIABILITIES			
Trade and other payables		338,057	284,874
Borrowings		217,000	210,000
Employee benefits		45,988	72,458
TOTAL CURRENT LIABILITIES		<u>601,045</u>	<u>567,332</u>
TOTAL LIABILITIES		<u>601,045</u>	<u>567,332</u>
NET ASSETS		<u>6,747,416</u>	<u>7,275,771</u>
EQUITY			
Issued capital	2	31,766,487	31,346,219
Reserves	3	5,193,610	3,689,386
Accumulated losses		(30,212,681)	(27,759,834)
TOTAL EQUITY		<u>6,747,416</u>	<u>7,275,771</u>

*The above consolidated statement of financial position
should be read in conjunction with the accompanying notes.*

**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE HALF-YEAR ENDED 31 DECEMBER 2016**

	Issued Capital	Share Based Payments Reserve	Accumulated Losses	Total
	\$	\$	\$	\$
Balance at 1 July 2015	25,232,558	2,533,528	(24,204,453)	3,561,633
Total comprehensive loss for the period	--	--	(1,185,313)	(1,185,313)
Shares issued during the period	6,787,000	--	--	6,787,000
Performance rights issued during the period	--	464,285	--	464,285
Transaction costs	(441,005)	--	--	(441,005)
Balance at 31 December 2015	<u>31,578,553</u>	<u>2,997,813</u>	<u>(25,389,766)</u>	<u>9,186,600</u>
Balance at 1 July 2016	31,346,219	3,689,386	(27,759,834)	7,275,771
Total comprehensive loss for the period	--	--	(2,452,847)	(2,452,847)
Shares issued during the period	425,210	--	--	425,210
Performance rights issued during the period	--	1,504,224	--	1,504,224
Transaction costs	(4,942)	--	--	(4,942)
Balance at 31 December 2016	<u>31,766,487</u>	<u>5,193,610</u>	<u>(30,212,681)</u>	<u>6,747,416</u>

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

**CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2016**

	31 Dec. 2016	31 Dec. 2015
	\$	\$
Cash flows from operating activities		
Receipts from customers	93,620	329,417
Payments to suppliers and employees	(1,793,492)	(1,972,564)
Interest received	100,453	96,458
Borrowing costs	(4)	(2)
	<hr/>	<hr/>
Net cash used in operating activities	(1,599,423)	(1,546,691)
	<hr/>	<hr/>
Cash flows from investing activities		
Payments for plant and equipment	(169,648)	(76,411)
	<hr/>	<hr/>
Net cash used in investing activities	(169,648)	(76,411)
	<hr/>	<hr/>
Cash flows from financing activities		
Proceeds from issue of shares and options	--	6,734,000
Transaction costs from issue of shares and options	(4,942)	(441,005)
	<hr/>	<hr/>
Net cash (used in)/provided by financing activities	(4,942)	6,292,995
	<hr/>	<hr/>
Net (decrease)/increase in cash and cash equivalents held	(1,774,013)	4,669,893
Cash and cash equivalents at the beginning of the financial period	7,334,205	3,519,337
Effect of exchange rate changes on cash holdings	(164)	2,376
	<hr/>	<hr/>
Cash and cash equivalents at the end of the financial period	<u>5,560,028</u>	<u>8,191,606</u>

*The above consolidated statement of cash flows
should be read in conjunction with the accompanying notes.*

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1: BASIS OF PREPARATION

The half-year consolidated financial report is a general purpose financial report prepared in accordance with the requirements of the *Corporations Act 2001* and Accounting Standard AASB 134: Interim Financial Reporting. Compliance with AASB 134 ensures that the financial report and notes also comply with International Financial Reporting Standard IAS 34: Interim Financial Reporting.

It is recommended that this consolidated financial report be read in conjunction with the annual financial report for the year ended 30 June 2016 and any public announcements made by OBJ Limited and its controlled entities during the half-year in accordance with the continuous disclosure requirements arising under the *Corporations Act 2001*.

The half-year consolidated financial report does not include full disclosures of the type normally included in annual financial reports.

Except for cash flow information, the half-year consolidated financial report has been prepared on an accruals basis and is based on historical costs.

The accounting policies have been consistently applied by the Consolidated Entity and are consistent with those in the 30 June 2016 annual financial report, except in relation to the matters disclosed below.

New and Revised Accounting Standards and Interpretations

The Consolidated Entity has adopted all of the new and revised Accounting Standards and Interpretations issued by the Australian Accounting Standards Board that are mandatory for the current reporting period. The adoption of these new and revised Accounting Standards and Interpretations has not resulted in a significant or material change to the Consolidated Entity's accounting policies.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted by the Consolidated Entity.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

NOTE 2: ISSUED CAPITAL

	Consolidated	
	31 Dec. 2016	30 Jun. 2016
	\$	\$
(a) Issued capital		
1,775,547,109 Ordinary shares fully paid (30/06/16: 1,770,137,109)	31,766,487	31,346,219
(b) Movements in ordinary share capital	Number of Shares	\$
01/07/2016 Opening balance	1,770,137,109	31,346,219
18/07/2016 In recognition of consultants' contribution to scientific advisory committee	1,000,000	80,000
18/07/2016 In recognition of employees' performance to the Company in accordance with the Company's E.S.O.P.	3,720,000	297,600
28/11/2016 Employees performance in accordance with performance milestones under the terms of employment contracts	690,000	47,610
Less: costs associated with the issue of shares		(4,942)
31/12/2016 Closing balance	1,775,547,109	31,766,487

NOTE 3: RESERVES

	Consolidated	
	31 Dec. 2016	30 Jun. 2016
	\$	\$
(a) Composition		
Share based payments reserve	5,193,610	3,689,386

The share based payments reserve records items recognised as expenses on valuation of director/employee/consultant share options and performance rights.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (*continued*)

NOTE 3: RESERVES (*continued*)

(b) Movements in options and performance rights were as follows:

Date	Details	Number of Performance Rights	Number of Options Listed	Number of Options Unlisted	Exercise Price	Fair Value of Options/Perf. Rights Issued	Expiry Date
01/07/16	Opening Balance	82,000,000	--	7,500,000	--	\$3,689,386	--
31/12/16	Add: value of performance rights carried forward from 30/06/16(refer Note 7)	--	--	--	--	\$1,504,224	28/11/17
31/12/16	Closing Balance	82,000,000	--	7,500,000		\$5,193,610	

NOTE 4: DIVIDENDS

There have been no dividends declared or recommended and no distributions made to shareholders or other persons during the period.

NOTE 5: SEGMENT INFORMATION

The Consolidated Entity has considered the requirements of AASB8 – Operating Segments and has identified its operating segments based on the internal reports that are reviewed and used by the board of directors (chief operating decision makers) in assessing performance and determining the allocation of resources.

The Consolidated Entity operates as a single segment which is development of the dermaportation drug delivery technology within Australia.

The Consolidated Entity is domiciled in Australia. All revenue from external parties is generated from Australia only. Segment revenues are allocated based on the country in which the party is located. Operating revenues of approximately \$122,143 or 8% (31/12/2015 – \$152,884 or 11%) are derived from a single external party.

All the assets are located in Australia only. Segment assets are allocated to countries based on where the assets are located.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)**NOTE 6: CONTINGENT ASSETS AND LIABILITIES**

The directors of the Company are unaware of any existing contingent assets and liabilities, other than the contingent liability matter regarding the Company being served with a writ over a convertible note, as previously announced to the market. The Company has retained legal representation for the active defence of the matter, to which mediation continues.

NOTE 7: SHARE BASED PAYMENTS

The total share based payment expense for the half-year ended recognised in the statement of comprehensive income was \$1,504,224, with the balance of \$1,290,868 to be carried forward and proportioned over the period up until the expiry date of 28 November 2017.

NOTE 8: EVENTS SUBSEQUENT TO REPORTING DATE

There has not arisen in the interval between the end of the half-year and the date of this report any item, transaction or event of a material and unusual nature likely, in the opinion of the directors of the Company, to affect significantly the operations of the Consolidated Entity, the results of those operations, or the state of affairs of the Consolidated Entity, in future financial years.


OBJ LIMITED
A.B.N. 72 056 482 636

DIRECTORS' DECLARATION

In the opinion of the directors:

- a) The financial statements and notes are in accordance with the Corporations Act 2001, including:
 - i) giving a true and fair view of the Consolidated Entity's financial position as at 31 December 2016 and of its performance for the half-year ended on that date; and
 - ii) complying with Australian Accounting Standards AASB 134: Interim Financial Reporting, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the board of directors pursuant to section 303(5)(a) of the Corporations Act 2001.



Jeffrey Edwards
Director

Dated this 27th day of February 2017

RSM Australia Partners

8 St Georges Terrace Perth WA 6000

GPO Box R1253 Perth WA 6844

T +61 (0) 8 92619100

F +61 (0) 8 92619111

www.rsm.com.au

**INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF
OBJ LIMITED**

We have reviewed the accompanying half-year financial report of OBJ Limited, which comprises the statement of financial position as at 31 December 2016, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration of the consolidated entity comprising the company and the entities it controlled at the half-year end or from time to time during the half-year.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2016 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of OBJ Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*. We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of OBJ Limited, would be in the same terms if given to the directors as at the time of this auditor's review report.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of OBJ Limited is not in accordance with the *Corporations Act 2001*, including:

- (a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2016 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

RSM

RSM AUSTRALIA PARTNERS



TUTU PHONG
Partner

Perth, WA
Dated: 27 February 2017